Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | AHCY | P23526 | 4/20 | 0.44 |
| ▸ | PI4KA | P42356 | 4/20 | 0.44 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.44 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL283730 | 0.88 | FGFR1 (0.51) | ADORA2AADORA1TAS1R3TAS1R1FGFR1 | |
| Acetone SCHEMBL28162073 | 0.82 | CYP3A4 (0.47) | ADORA2AADORA1TAS1R3TAS1R1FGFR1 | |
| SCHEMBL27721221 | 0.80 | FGFR1 (0.47) | ADORA2AADORA1TAS1R3TAS1R1FGFR1 | |
| SCHEMBL1035726 | 0.80 | ENPP1 (0.51) | FGFR1SLC22A6CYP3A4ENPP1 | |
| Furan SCHEMBL28181037 | 0.79 | FGFR1 (0.44) | ADORA1TAS1R3TAS1R1FGFR1SLC22A6 | |
| SCHEMBL8509835 | 0.79 | ENPP1 (0.50) | ADORA1FGFR1SLC22A6CYP3A4ENPP1 | |
| SCHEMBL502621 | 0.79 | ENPP1 (0.52) | FGFR1SLC22A6ENPP1 | |
| SCHEMBL385843 | 0.78 | ADORA2A (0.55) | ADORA2AADORA1AHCYPI4KAPI4K2B | |
| SCHEMBL6334793 | 0.78 | FGFR1 (0.61) | ADORA2AADORA1TAS1R3TAS1R1FGFR1 | |
| SCHEMBL27903676 | 0.76 | CYP3A4 (0.47) | ADORA2AADORA1FGFR1SLC22A6AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114057816-A | Adenine-rich phosphorothioate oligonucleotide and application thereof in resisting hepatitis virus | 浙江柏拉阿图医药科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| CN-114057816-B | Adenine-enriched phosphorothioate oligonucleotide and application thereof in resisting hepatitis virus | 浙江柏拉阿图医药科技有限公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-114057816-A | Adenine-rich phosphorothioate oligonucleotide and application thereof in resisting hepatitis virus | 浙江柏拉阿图医药科技有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-9221868-B2 | Uridine di- or tri-phosphate derivatives and uses thereof | BAR-ILAN UNIVERSITY (IL) | 2015-12-29 | — | — | US | disclosed |
| EP-2646449-B1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | UNIV BAR ILAN (IL) | 2015-08-19 | — | — | EP | disclosed |
| EP-2380897-B1 | RNAi modulation of ApoB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2015-05-13 | — | — | EP | disclosed |
| EP-2377873-B1 | RNAi modulation of ApoB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20130324495-A1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | UNIVERSIDAD COMPLUTENSE DE MADRID (ES) | 2013-12-05 | — | — | US | disclosed |
| EP-2646449-A1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | Bar-Ilan University (IL) | 2013-10-09 | — | — | EP | disclosed |
| WO-2012073237-A1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | BAR-ILAN UNIVERSITY (IL) | 2012-06-07 | — | — | WO | disclosed |
| CN-101133074-A | RNAi modulation of APOB and uses thereof | ALNYLAM PHARMACEUTICALS INC (US) | 2008-02-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324495-A1 | URIDINE DI- OR TRI-PHOSPHATE DERIVATIVES AND USES THEREOF | P2RY6, UMPS, P2RY1 | ADORA2A 45/4885ADORA1 42/4885TAS1R3 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.